Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

Condition:   Multiple Myeloma Interventions:   Drug: Daratumumab SC in combination with Lenalidomide;   Drug: Lenalidomide PO (25mg);   Drug: Dexamethasone PO (20mg): days 1, 8, 15, 22 of each 28-day cycle, until progression Sponsor:   University Hospital, Lille Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials